All these data suggest that pharmacological inhibition of KDM1A by GSK-LSD1 can inhibit thyroid cancer progression and sensitize it to chemotherapy, and therefore, targeting KDM1A may bea novel therapeutic strategy for patients with advanced thyroid cancer. The gene discussed is KDM1A; the disease is thyroid cancer.